Abstract
We investigated the distribution of the magnetic resonance imaging (MRI)-measured response to glatiramer acetate (GA) treatment in multiple sclerosis (MS) using data from a clinical trial of relapsing-remitting (RR) MS. A fixed and a random effects model were used to quantify the between-patient heterogeneity in treatment response, expressed as new enhancing lesion percentage reduction. In 95% of the patients, lesion reduction due to treatment was estimated to range between -20% and -54%, indicating a rather homogeneous effect of GA on MRI-measured disease activity in RRMS.
Original language | English |
---|---|
Pages (from-to) | 447-449 |
Number of pages | 3 |
Journal | Multiple Sclerosis Journal |
Volume | 11 |
Issue number | 4 |
DOIs | |
Publication status | Published - Aug 2005 |
Keywords
- MRI lesions
- Multiple sclerosis
- Shape of GA effect
ASJC Scopus subject areas
- Clinical Neurology